Invasion by esophageal cancer cells: Functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor

Clinical and Experimental Metastasis

Volumn 17, Issue 1, 1999, Pages 77-85

  Morrissey, Darrin ^a   O'Connell, Joe ^a,b   Lynch, Deirdre ^a   O'Sullivan, Gerald C ^a   Shanahan, Fergus ^a   Collins, J Kevin ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b Department of Medicine National University of Ireland Cork   (Ireland)

Author keywords

Antisense treatment; Human esophageal carcinoma cell lines; Invasion; Urokinase; Urokinase receptor

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; MATRIGEL; PLASMINOGEN; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; ESOPHAGUS CANCER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS; PLASMINOGEN ACTIVATION;

DNA, COMPLEMENTARY; ESOPHAGEAL NEOPLASMS; HUMANS; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDES, ANTISENSE; RECEPTORS, CELL SURFACE; TRANSFECTION; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032984011     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Hart IR, Saini A. Biology of tumor metastasis. Lancet 1992; 339: 1453-57.
2. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161-95.
3. Ossowski L, Biegel D, Reich E. Mammary plasminogen activator: correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue. Cell 1979; 16: 929-40.
4. Beers WH, Strickland S, Reich E. Ovarian plasminogen activator: relationship to ovulation and hormonal regulation. Cell 1975; 6: 387-94.
5. Strickland S, Reich E, Sherman MI. Plasminogen activator in early embryogenesis: enzyme production by trophoblast and parietal endoderm. Cell 1976; 9: 231-40.
6. Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes, J Biol Chem 1989; 264: 2185-8.
7. Grondahl-Hamsen J, Lund LR, Ralfkiaer E et al. Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. J Invest Dermatol 1988; 90: 790-5.
8. Kwaan HC. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 1992; 11: 291-311.
9. Dano K, Andreasen PA, Grondahl-Hansen J, et al. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
10. Blasi F. Surface receptors for urokinase plasminogen activator. Fibrinolysis 1988; 2: 27-84.
11. Rao JS, Steck PA, Tofilon P et al. Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model. J Neurooncol 1993; 18: 129-38.
12. De Vries JE, Dinjens WN, De Bruyne GK et al. In vivo and in vitro invasion in relation to phenotypic characteristics of human colorectal carcinoma cells. Br J Cancer 1995; 71: 271-7.
13. Ossowski L. Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res 1992; 52: 6754-60.
14. Stahl A, Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994; 54: 3066-71.
15. Kobayashi H, Ohi H, Shinohara H et al. Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion. Br J Cancer 1993; 67: 537-44.
16. Kook YH, Adamski J, Zelent A, Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 1994; 13: 3983-91.
17. Go Y, Chintala SK, Mohanam S et al. Inhibition of in vivo tumourigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPA-R vectors. Clin Expl Metastasis 1997; 15: 440-6.
18. Quattrone A, Fibbi G, Anichini E et al. Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res 1995; 55: 90-5.
19. Engelhard H, Narang C, Homer R, Duncan H. Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity. Biochem Biophys Res Commun 1996; 227: 400-5.
20. O'Mahony AM, O'Sullivan GC, O'Connell J et al. An immune suppressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage. J Immunol 1993; 151: 4847-56.
21. O'Sullivan GC, Corbett A, Collins JK, Shanahan F. Regional immune suppression in esophageal squamous cancer: evidence from functional studies with matched lymph nodes. J Immunol 1997; 157: 4717-20.
22. Walsh, TN, Noonan N, Hollywood D et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-7.
23. Sier CFM, Verspaget HW, Griffonen G et al. Plasminogen activators in normal tissue and carcinomas of the human esophagus and stomach. Gut 1993; 34: 80-5.
24. Hewin DF, Savage PB, Aldersen D, Vipond MN et al. Plasminogen activators in esophageal carcinoma. Br J Surg 1996; 83: 1152-5.
25. Collins JK, O'Mahony A, O'Brien F et al. Evaluation of newly established cell lines as models to study growth, invasion and metastatic spread in oesophageal cancer. Fibrinolysis 1992; 6: 83-8.
26. Capaccioli S, Di Pasquale G, Mini E et al. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem Biophys Res Commun 1993; 197: 818-25.
27. Chomezynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1985; 162: 156-9.
28. Riccio A, Grimaldi G, Verde P et al. The human urokinase-plasminogen activator gene and its promoter. Nucleic Acids Res 1985; 13: 2759-71.
29. Roldan AL, Cubellis MV, Masucci MT et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990; 9: 467-74.
30. Schlechte W, Brattain M, Boyd D. Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display. Cancer Commun 1990; 2: 173-9.
31. Twentyman PR, Luscombe M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 1987; 56: 279-85.
32. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas Counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-82.
33. Degols G, Leonetti JP, Mechti N, Lebleu B. Antiproliferative effects of antisense oligonucleotides directed to the RNA of c-myc oncogene. Nucleic Acids Res 1991; 19: 945-8.
34. Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumour metastasis. Cell 1983; 35: 611-9.
35. Kobayashi H, Ohi H, Sugimura M et al. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 1992; 52: 3610-4.
36. Ossowski L, Russo-Payne H, Wilson EL. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 1991; 51: 274-81.
37. Kramer MD, Spring H, Todd RF, Vettel U. Urokinase-type plasminogen activator enhances invasion of human T cells (Jurkat) into a fibrin matrix. J Leukoc Biol 1994; 56: 110-6.
38. Kariko K, Kuo A, Boyd D et al. Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Cancer Res 1993; 53: 3109-17.
39. Mohanam S, Chintala SK, Go Y et al. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene 1997; 14: 1351-9.
40. Gyetko MR, Todd RF, Wilkinson CC, Sitrin RG The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 1994; 93: 1380-7.
41. Mohanam S, Sawaya R, McCutcheon I et al. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res 1993; 53: 4143-7.
42. Crowley CW, Cohen RL, Lucas BK et al. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993; 90: 5021-5.
43. Willhelm O, Weidle U, Hohl S et al. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett 1994; 337: 131-4.